• Transgene posted a net loss of EUR 15.67 million for H1 2026, narrowing from EUR 19.3 million a year earlier.
• Operating loss narrowed to EUR 16.74 million, while operating income fell 34.64% to EUR 2.99 million.
• Cash and equivalents totaled EUR 92.8 million at June 30, down from EUR 111.9 million at Dec. 31.
• Cash burn rose to EUR 20.3 million, and financial visibility was reiterated through early 2028 under current plans.
• TG4050 Phase 2 recruitment finished, TG4070 Phase 1 started, and TG-MVA advanced toward clinical development on positive preclinical data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241145PRIMZONEFULLFEED1001274462) on September 24, 2026, and is solely responsible for the information contained therein.